Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.
Investors kidneyintelX.dkd

About Graham Dyer

This author has not yet filled in any details.
So far Graham Dyer has created 4 blog entries.

MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities

Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with kidneyintelX.dkd , the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, and MVP Health Care ("MVP") , a not-for-profit health insurer that provides services to 700,000 members in the northeastern part of the United States, have joined forces to mitigate the progression of chronic kidney disease in their insured type 2 diabetes patient population.


Read More
By |2025-07-21T20:53:27+00:0007.17.25|News|Comments Off on MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities

Growing collaboration with NYKHM

LONDON and NEW YORK, 3 June 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company, announces a collaboration with New York Kidney & Hypertension Medicine (NYKHM) to expand access to kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in patients with type 2 diabetes and chronic kidney disease stages 1-3b.


Read More
By |2025-06-11T13:09:09+00:0006.03.25|News|Comments Off on Growing collaboration with NYKHM

Management Change

LONDON and SALT LAKE CITY - 28 May 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that O. James Sterling will step down from his role as Chief Financial Officer of the Company as of 24 May 2024 and will remain at the Company until 10 June 2024. The Board has appointed Joel R. Jung as Interim Chief Financial Officer, effective immediately while a handover period takes place.

By |2024-05-29T09:46:31+00:0005.29.24|News|Comments Off on Management Change

Management Change

LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “ Ordinary Shares ”) (the “


Read More
By |2024-04-18T17:17:12+00:0004.18.24|News|Comments Off on Management Change
Go to Top